Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.

Détails

Ressource 1Télécharger: 26449988_BIB_75B4A28E2617.pdf (500.00 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_75B4A28E2617
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Périodique
Bmc Cancer
Auteur(s)
Dell'Ova M., De Maio E., Guiu S., Roca L., Dalenc F., Durigova A., Pinguet F., Bekhtari K., Jacot W., Pouderoux S.
ISSN
1471-2407 (Electronic)
ISSN-L
1471-2407
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
15
Numéro
1
Pages
659
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: epublish
Résumé
BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting.
METHODS: Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. Clinical and biological assessment of toxicity was performed at each visit. Tumour response was assessed every 3 cycles of treatment. A database was created to collect clinical, pathological and treatment data.
RESULTS: Two hundred and fifty-eight patients were included in the study. Median age was 59 years old. Tumours were Hormone Receptor (HR)-positive (73.3 %) HER2-positive (10.2 %), and triple negative (TN, 22.5 %). 86.4 % of the patients presented with visceral metastases, mainly in the liver (67.4 %). Median previous metastatic chemotherapies number was 4 [1-9]. Previous treatments included anthracyclines and/or taxanes (100 %) and capecitabine (90.7 %). Median number of EM cycles was 5 [1-19]. The relative dose intensity was 0.917. At the time of analysis (median follow-up of 13.9 months), 42.3 % of the patients were still alive. The objective response rate was 25.2 % (95 %CI: 20-31) with a 36.1 % clinical benefit rate (CBR). Median time to progression (TTP) and overall survival were 3.97 (95 %CI: 3.25-4.3) and 11.2 (95 %CI: 9.3-12.1) months, respectively. One- and 2-year survival rates were 45.5 and 8.5 %, respectively. In multivariate analysis, HER2 positivity (HR = 0.29), the presence of lung metastases (HR = 2.49) and primary taxanes resistance (HR = 2.36) were the only three independent CBR predictive factors, while HR positivity (HR = 0.67), the presence of lung metastases (HR = 1.52) and primary taxanes resistance (HR = 1.50) were the only three TTP independent prognostic factors. Treatment was globally well tolerated. Most common grade 3-4 toxicities were neutropenia (20.9 %), peripheral neuropathy (3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %) and thrombocytopenia (0.4 %). Thirteen patients (5 %) developed febrile neutropenia.
CONCLUSION: EM is an effective new option in heavily pretreated MBC, with a favourable efficacy/safety ratio in a clinical practice setting. Our results comfort the use of this new molecule and pledge for the evaluation of EM-trastuzumab combination in this setting. Tumour biology, primary taxanes sensitivity and metastatic sites could represent useful predictive and prognostic factors.
Mots-clé
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Biomarkers, Tumor, Breast Neoplasms/diagnosis, Breast Neoplasms/drug therapy, Drug Resistance, Neoplasm, Female, Furans/pharmacology, Furans/therapeutic use, Humans, Ketones/pharmacology, Ketones/therapeutic use, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Retrospective Studies, Taxoids/pharmacology, Treatment Outcome, Young Adult
Pubmed
Web of science
Open Access
Oui
Création de la notice
27/10/2015 18:17
Dernière modification de la notice
08/05/2019 20:31
Données d'usage